01 — At a Glance
When Hospitals Start Playing Monopoly With Real Money
- 52-Week High / Low₹1,105 / ₹521
- Q3 Revenue₹2,265 Cr
- Q3 PAT₹197 Cr*
- Q3 EPS₹2.57
- Annualised EPS (Q3×4)₹10.28
- Book Value₹125
- Price to Book7.15x
- Dividend Yield0.11%
- Debt / Equity0.34x
- Net Debt₹2,547 Cr
Quarterly Snapshot: Fortis closed Q3 FY26 with ₹2,265 crore revenue (+17.5% YoY), ₹505 crore operating EBITDA (+34.8% YoY), and 22.3% EBITDA margin expansion. The reported PAT of ₹197 crore was hit by ₹55 crore one-off Labour Code expense (partly offset by ₹9 crore impairment reversal). Strip out the noise, and pre-exceptional earnings were ₹312 crore (+21.9% YoY). The stock, trading at 66.9x P/E and 7.15x book value, has turned into a high-conviction hospital play for those patient enough to believe in 10–12% revenue CAGRs.
02 — Introduction
The Hospital Chain That Went From Scandal to Acquisition Spree
Fortis Healthcare has had a more dramatic life story than a Netflix series. Founded in 1996, it became a household name in private healthcare. Then, in 2015–2018, it imploded under the weight of massive debt and shocking founder fraud—the Singh brothers went to jail, the company was essentially seized, and shareholders got wiped. By 2018, Malaysian healthcare giant IHH Healthcare stepped in as the white knight, bought a 31% controlling stake for ₹4,000 crore, and has been quietly rebuilding ever since.
Fast forward to Q3 FY26 (December 31, 2025). Fortis isn’t just surviving—it’s thriving. Operating 33 hospitals across India with 5,700+ operational beds, a diagnostics network (Agilus) with 4,370+ customer touchpoints conducting 40+ million tests annually, and management that actually seems to know what it’s doing. The company has gone from barely profitable to posting ₹950 crore+ annual operating cash flow.
Oh, and they’re acquiring hospitals like they’re collecting Pokémon cards. In the last quarter alone, they bought People Tree Hospital in Bengaluru for ₹430 crore (with plans to add another 175 beds), completed Jalandhar acquisition, and are eyeing more. The debt levels crept up, but management keeps insisting the balance sheet has “room for more.” We’ll believe it when the credit rating agencies do.
From the Concall (Feb 2026): “The debt/EBITDA number is not that alarming… still room to take some more debt,” per management on leverage headroom post-acquisition. Confidence or recklessness? The spread between those two is what equity investors are being paid for.
03 — Business Model: Cash Extraction From Sick People (Ethically)
Hospitals + Diagnostics + M&A = The Desi Healthcare Playbook
EduInvesting runs entirely on reader support — ₹360 a year keeps the lights on.
